20.109(S15):Flow cytometry and paper discussion (Day6): Difference between revisions

From OpenWetWare
Jump to navigationJump to search
 
(23 intermediate revisions by the same user not shown)
Line 11: Line 11:
[[Image:S14M2_Grundy-NHEJ-overview.png|thumb|center|400px|NHEJ pathway overview from GJ Grundy et al., "One ring to bring them all—The role of Ku in mammalian non-homologous end joining" in ''DNA Repair'' 2014 TBD, in press]]
[[Image:S14M2_Grundy-NHEJ-overview.png|thumb|center|400px|NHEJ pathway overview from GJ Grundy et al., "One ring to bring them all—The role of Ku in mammalian non-homologous end joining" in ''DNA Repair'' 2014 TBD, in press]]


To better understand how DNA-PKcs may differ from Ku80 as a target for changing a cell’s DNA damage response, let’s take a closer look at Compound 401. A number of small molecule inhibitors of DNA-PK were [http://www.ncbi.nlm.nih.gov/pubmed/15658870 discovered by Griffin et al.] in the early 2000s. While both Griffin and the commercial vendor Tocris/R&D Systems refer to the inhibitors generically as DNA-PK rather than DNA-PKcs inhibitors per se, it is clear that the "cs" is implied and kinase activity is what is being inhibited. The inhibitor is described as “ATP-competitive,” indicating that it competes for the ATP binding pocket in the kinase domain of DNA-PK. Moreover, the Griffin inhibition assay used p53 phosphorylation as a readout, rather than phosphorylation after binding to Ku 70/80. Finally, the inhibitor also acts on the unrelated kinase mammalian target of rapamycin (mTOR).
The one piece of wet lab work that you will do next time is complete your NHEJ inhibitor validation assay. Clonogenic assays of mammalian cells have over a 50 year history, as mentioned in the [http://www.ncbi.nlm.nih.gov/pubmed/17406473 '''methods paper by Franken et al'''.] They are useful for assessing the reproductive capacity of cells after irradiation and other types of damage. We will diverge somewhat from the Nature Protocols paper, but it is useful for introducing terms such as the plating efficiency and the surviving fraction. Specifically, we do not need to fix our cells in an independent step, because the stain that we will use contains methanol. ('''Correction!''' Our stain contains very little methanol, so fixing does not appear crucial for short-term staining.) Second, we will not use the crystal violet stain, which binds DNA, but instead a Coomassie derivative, which targets proteins. In fact, you may recognize Coomassie as the go-to stain for SDS-PAGE. Protein binding by the dye occurs primarily via arginine, as well as other basic and aromatic residues, as described [http://www.ncbi.nlm.nih.gov/pubmed/4096375 here]. We will use a variant of the original Coomassie Brilliant Blue stain called BioSafe Coomassie.


The one piece of wet lab work that you will do today is completing the C401 validation assay. Clonogenic assays of mammalian cells have over a 50 year history, as mentioned in the [http://www.ncbi.nlm.nih.gov/pubmed/17406473 '''methods paper by Franken et al'''.] They are useful for assessing the reproductive capacity of cells after irradiation and other types of damage. We will diverge somewhat from the Nature Protocols paper, but it is useful for introducing terms such as the plating efficiency and the surviving fraction. Specifically, we do not need to fix our cells in an independent step, because the stain that we will use contains methanol. ('''Correction!''' Our stain contains very little methanol, so fixing does not appear crucial for short-term staining.) Second, we will not use the crystal violet stain, which binds DNA, but instead a Coomassie derivative, which targets proteins. In fact, you may recognize Coomassie as the go-to stain for SDS-PAGE. Protein binding by the dye occurs primarily via arginine, as well as other basic and aromatic residues, as described [http://www.ncbi.nlm.nih.gov/pubmed/4096375 here]. We will use a variant of the original Coomassie Brilliant Blue stain called BioSafe Coomassie.
Most of your time today will be spent at the computer, quantifying flow cytometry data. Recall from the M2D4 introduction that we will proceed in three main steps.  


Most of your time today will be spent at the computer, quantifying flow cytometry data. Recall from the M2D5 introduction that we will proceed in three main steps.  
First, reporter expression for GFP and BFP alike will be calculated by multiplying percentage of positive cells by fluorescence intensity (FI). We have a choice of whether to use mean, geometric mean, or median fluorescence intensity. Median fluorescence is least susceptible to being influenced by a few outliers, while geometric mean is generally more appropriate for log scale data than arithmetic mean. For normally distributed populations, all three values should be pretty similar. In practice, we have found that while mean and median FI are very different values, after normalization the ultimate NHEJ repair values are quite similar, so we will use the mean value.


First, reporter expression for GFP and BFP alike will be calculated by multiplying percentage of positive cells by fluorescence intensity (FI). Here we have a choice of whether to use mean, geometric mean, or median fluorescence intensity. Median fluorescence is least susceptible to being influenced by a few outliers, while geometric mean is generally more appropriate for log scale data than arithmetic mean. For normally distributed populations, all three values should be pretty similar. In practice, we have found that while mean and median FI are very different values, after normalization the ultimate NHEJ repair values are quite similar.
The second step is to calculate the ratio of BFP to GFP reporter expression for each sample. The final step is divide the damaged-BFP:GFP ratio by the maximal possible “repair,” namely the intact-BFP:GFP ratio. Convince yourself that this parameter essentially provides the fraction of BFP plasmids repaired.
 
The second step is to calculate the ratio of BFP to GFP reporter expression for each sample. Whereas during pilots this ratio tended to be greater than 1.0, a preliminary look at our class-wide data suggests that it is now very close to 1.0. This shift could easily be caused by periodic adjustments to and calibration of the flow cytometry equipment, including the lasers. In fact, during set-up with the instructor samples, the voltage for the FSC as well as a more complex scatter parameter that we haven’t discussed both had to be adjusted from pilot values. This outcome highlights why it’s so important  – perhaps when taking your own flow data some day – to perform both flow controls (negative and single color) and experimental controls (here dual intact) every single time one does an experiment!
 
The final step is divide the damaged-BFP:GFP ratio by the maximal possible “repair,” namely the intact-BFP:GFP ratio. Convince yourself that this parameter essentially provides the fraction of BFP plasmids repaired.


==Protocols==
==Protocols==
Line 27: Line 23:
===Part 1: Paper discussion===
===Part 1: Paper discussion===


As described in the Day 5 FNT, we will be discussing the in class today.  
As described in the Day 5 homework, we will be discussing the[[Media:M2D6paperS15.pdf | Goglia et al.]] paper in class today.  


====Technical Background====
====Technical Background====
The paper by Goglia et al. utilizes a fluorescence based DNA repair sensor similar to the one that you are employing in Module 2. There are, however, some important differences in the construction and function of the EJ-RFP (end joining-red fluorescent protein) sensor versus the pMAX-BFP-MCS sensor that was constructed for 20.109. Another paper from the same lab, [http://nar.oxfordjournals.org/content/41/11/e115.long published in 2013], details the development of the EJ-RFP sensor. You do not need to read the entire paper, but make sure that you understand how the sensor works so that you can fully grasp the high throughput screen that was completed in the Goglia et al. manuscript.
In particular, please read the Introduction and the first two Results sections of the 2013 paper. You will find this [[Media:BackgroundInformation_S15.pdf | background presentation]] to be helpful for understanding the DNA repair sensors in the Goglia et al. paper.


====Discussion Topics====
====Discussion Topics====


=====Writing=====


*How does this abstract style differ from the one you have previously encountered – and also explicitly been taught – in 20.109? How is it the same? What are the pros and cons of each format? As a whole, did the abstract make you want to read the paper?
*This Introduction is short but packs a punch. With the [[20.109%28S15%29:Guidelines_for_writing_up_your_research#Introduction | '''20.109 guidelines''']] in mind, locate the key elements of an introductory section here. What one sentence best defines the research gap?
*Let's pay special attention to the Methods section, since you will be writing one during Module 2!
**What best practices for Methods section writing do the authors follow? For example, do they write clear topic sentences of appropriate scope?
**What is the authors' strategy for sub-section groupings? What is the role of the first sub-section?
**What methods do the authors seem to assume that most readers will be familiar with?
**What methods do the authors seem to assume need more detailed definition or citation?
**What is the purpose of a passage beginning "Briefly, …"?
**Are there any changes you would suggest the authors make?
*We'll talk about the writing style in the Results and Discussion sections in tandem with our conversation about the technical content. Remember to keep in mind
**[[20.109%28S15%29:Guidelines_for_writing_up_your_research#Results | '''Results guidelines''']],
**[[20.109%28S15%29:Guidelines_for_writing_up_your_research#Discussion | '''Discussion guidelines''']], and
**[[20.109%28S15%29:Guidelines_for_writing_up_your_research#Results_vs._Discussion | '''differences between the two''']].


=====Content=====
=====Content=====


The following questions will guide our in-class discussion; consider them as a starting point rather than a check-list.
The following questions will guide our in-class discussion; consider them as a starting point rather than a check-list.
'''(A) DNA repair background'''
#What is the difference between canonical NHEJ and (what the authors term) mutagenic NHEJ? What type of NHEJ does your sensor measure?
#How did the authors develop a specific screening tool for mNHEJ versus cNHEJ?
'''(B) Drug screening background'''
#What is the difference between a "reverse chemical genetic" screen and a "forward chemical genetic" screen? Why would you use one versus the other?
#What type of equipment did the authors use to perform the drug screen? Think about a couple reasons why this would be not only convenient, but also important for the study.
#Why was DMSO added at 1% in wells not containing drug?
#What was the purpose of adding Shield1 and TA? The authors state that the "absence" of these ligands is a positive control. What do they mean?
#What is an orthogonal assay? What is the purpose of performing these types of assays?
#What orthogonal assays were performed to confirm the original hits?
=====Figures & Results=====
We will not discuss all of the figures in this paper. Concentrate on the Results sub-sections and Figures outlined below. Be prepared to discuss all of the figures listed below. It is completely fine to have questions about the paper and to not fully grasp all of the material, but it is expected that you will have put forth a good faith effort to do so.
#'''Figure 1'''
#*Figures 1A and 1B are typical schematic diagrams that you find within journal papers. Why are these helpful and what specific information do you obtain from these sub-panels?
#*Figure 1C provides an example of the type of output data obtained. What factors do the authors report are important to achieve adequate cell segmentation?
#*The remainder of Figure 1 shows important control experiments. Answer the following questions while you read:
#**What controls are shown and why is it important to show these controls in a figure?
#**What is a Z'-factor and why do the authors use it?
#**Do you feel convinced that the data obtained in the large inhibitor screen will be believable after reading about and examining Figure 1?
#'''Figure 2'''
#*What is a RADaR plot and how do you read it? (Part of ''selling'' your science is coming up with memorable acronyms.)
#*Explain the significance of Figures 2B and 2C.
#*Why did the authors start with the LOPAC 1280 library (and what is it)?
#'''Figure 3'''
#*This figure shows a graphical representation of the 20,000 compound screen. How many times was this replicated? Where did the 20,000 compound library come from?
#'''Figure 4'''
#*This is another great example of an useful schematic diagram in this paper. Consider all of the information that is contained in this small flowchart and, as you read, keep track of how many times you reference it.
#*As you put together your Mod2 report, think about how you might use schematic diagrams to help the reader understand your study.
#'''Figure 5'''
#*What is RU-0084411 and why is it an interesting ''hit'' in the screen? Why might the authors (and pharmaceutical companies) be especially interested in following up on this type of hit?
#*The curves shown under Figure 5A-2&3 are generally referred to as 'dose-response' or 'inhibition' curves. Many dose-response curves have a sigmoidal shape. How does one estimate the IC50 from analyzing this type of data?
#*Do any of the plots shown in Figure 5A give you pause with respect to future use of Mibrefradil as a clinical NHEJ inhibitor?
#'''Figure 6'''
#*What is an orthogonal assay in the context of this paper? Why is it important to do them?
=====Discussion & Conclusions=====
Please read the entirety of the Discussion section.
*List three reasons why the authors state that their study is novel. What type of evidence do they use to convince you?
*List a couple limitations of the paper (that the authors address in this section).
The purpose of a Discussion section is (at least) four-fold:
#'''Provide a summary and explanation of the data in the paper.''' This is the place to do all of your interpretation. For example, in the third paragraph of the Discussion section that starts "We identified several novel molecules...", the authors admit to being surprised at some of their findings. They then postulate why these findings might be real and suggest further studies that would be required to further tease apart the current data.
#'''Convince the audience that your study makes a contribution to the field.''' The Discussion section is the place to compare and contrast your current results with those that have already been published. Why are your results interesting and important? Re-visit your Introduction -- what was your 'big picture' motivation? How did your study impact that?
#'''Admit your limitations.''' No study is perfect, don't let anyone tell you that it is! Perhaps your data doesn't quite get to the answer and there is a technical limitation -- tell the audience. Perhaps the cell system you are using isn't the optimal one (which may or may not be available) -- tell the audience. Perhaps the data from your DNA repair assay is noisy and you know why -- tell the audience. The Discussion section should admit to limitations and suggest specific ways to address them.
#'''Suggest the next big thing.''' Where does your study leave off? Since you are now the expert -- what is the next most important thing to do?!?


===Part 2: Flow cytometry analysis===
===Part 2: Flow cytometry analysis===
Line 61: Line 99:


'''Protocol:'''
'''Protocol:'''
#On one of the lab computers, double-click on the FACS server shortcut.
#The pdf files with your data are posted on the M2D6 Talk page.
#*Alternatively, on your own computer access 18.159.2.11 directly. Ask your instructors for the username and password.
#Go to the ''April 2014'' folder, then to ''Agi Stachowiak''. Copy over both the T/R and W/F image sets to your laptop: the filenames begin "analysis-images" and only the dates differ.
#Copy over just your own day of statistics, unless you really want access to all of the raw data in your back pocket: the .csv filenames begin "analysis-statistics" and only the dates differ.
#The instructor samples are listed in the table below. From this table, and from the T/R and W/F image sets, try to address the questions below.
#The instructor samples are listed in the table below. From this table, and from the T/R and W/F image sets, try to address the questions below.
#*Background. The scatter data is used – in three steps – to make gate P3, which should consist primarily of live, single cells. From the cells gated in P3, two sub-gates are made that capture all GFP-positive cells ("Green cells" gate) and all BFP-positive cells ("Blue cells" gate). Both singly and doubly positive cells are included in each gate. It is important to read the "% Parent" statistics: these indicate XFP-positive cells as a percentage of all the cells in P3. The "% Total" statistics include debris, aggregates, and clearly dead cells!
#*Background. The scatter data is used – in three steps – to make gate P3, which should consist primarily single cells. Next a gate that we called '''Live cells''' was set based upon the addition ToPro3 to the media. ToPro3 can only pass through the membranes of dead cells, staining them with a dye that fluoresces when exited with 647 nm wavelength light. The cytometer we used calls this channel the '''APC''' channel (because the dye APC also fluoresces at that wavelength). So, using the plot that shows FSC vs APC we can ''gate-in'' the live cells (exclude the dead ToPro3+ cells).
#From the cells gated in Live Cells, two sub-gates are made that capture all GFP-positive cells ("Green cells" gate) and all BFP-positive cells ("Blue cells" gate). Both singly and doubly positive cells are included in each gate. It is important to read the "% Parent" statistics: these indicate XFP-positive cells as a percentage of all the cells in Live Cells. The "% Total" statistics include debris, aggregates, and clearly dead cells!
#*What percent Green cells are in the mock sample on each day? What about Blue cells?
#*What percent Green cells are in the mock sample on each day? What about Blue cells?
#*What percent of singly-transfected cells express GFP? Do within-day and cross-day replicates agree well or not?  
#*What percent of singly-transfected cells express GFP? Do cross-day replicates agree well or not?  
#*What percent of singly-transfected cells express BFP? Do within-day and cross-day replicates agree well or not?  
#*What percent of singly-transfected cells express BFP? Do cross-day replicates agree well or not?  
#*What percent of co-transfected cells express GFP? Express BFP? Comparing the Green and Blue gates to Q1 and Q4, about what percent of cells seem co-transfected, versus expressing just GFP, and expressing just BFP?  
#Now, start to look at your K1-intact conditions (and possibly those of your classmates).
#*How is within-day and cross-day replicate agreement for the co-transfected samples? Do the tables below suggest an explanation for why?
#*What percent of co-transfected cells express GFP? Express BFP? How many express both?  
#*Does ethanol appear to affect scatter profiles? What about affecting GFP, BFP, or co-expression?
#*How is within-day and cross-day replicate agreement for the co-transfected samples?  
#*What NHEJ repair value do you calculate for Zac's original BFP plasmid, using the first replicate in the W/F instructor data? Try this calculation by hand, using the mean fluorescence intensity. Later, you can include this data as a check on your Excel worksheet. The value you should calculate is 12.8%.<font color=red>Update: Your instructor picked off GFP mean fluorescence instead of BFP mean fluorescence for the intact case! Here is where computers definitely beat manual picking off of data. The correct number is '''8.7%'''.</font color>
#Answer the following by looking at a team that used DMNB (hint: there is a spreadsheet on the Talk page that will help you locate those samples).
#After you understand the instructor data, skim over your 12 sample plots. Can you see apparent differences between K1, K1+401, and xrs6?  
#*Does DMSO appear to affect scatter profiles? What about affecting co-expression?
#*Hint: you'll need to compare the K1 intact samples from a DMNB group versus a different group.
#After you understand the instructor data, skim over your 12 sample plots. Can you see apparent differences between K1, K1+inhibitor, and xrs6?  
#Now that you have a good conceptual understanding of the data, it's time to crunch some numbers. Open the .csv file and save it as a newly named .xlsx file.  
#Now that you have a good conceptual understanding of the data, it's time to crunch some numbers. Open the .csv file and save it as a newly named .xlsx file.  
#Begin by deleting all of the rows except the twelve containing your own dataset.
#Begin by deleting all of the rows except the twelve containing your own dataset.
#Next delete all of the columns except the few that interest you. Keep in mind that you need to know Green cell and Blue cell gating as a % of the parent gate, P3. Class-wide, you are only required to do your calculations based on mean fluorescence intensity (MFI), to be consistent with Samson lab data. However, you may find it interesting to see whether using median fluorescence intensity gives you the same trends or not. Just a few extra copy-pastes to do both calculations!
#Next delete all of the columns except the few that interest you. Keep in mind that you need to know Green cell and Blue cell gating as a % of the parent gate, Live Cells. Class-wide, you are only required to do your calculations based on mean fluorescence intensity (MFI), but you should also keep the median data in case others want to use it.
#We recommend that you prepare a new Excel file with your NHEJ equations, and just copy-paste in the appropriate % and MFI data; this approach is a versatile one. Your final worksheet might look similar to the screenshot below.
#We recommend that you prepare a new Excel file with your NHEJ equations, and just copy-paste in the appropriate % and MFI data; this approach is a versatile one. Your final worksheet might look similar to the screenshot below.
#Remember that for each of the twelve wells you should calculate raw reporter expressions and a BFP/GFP normalized value. Then, for each intact/cut pair you can calculate an NHEJ value. In this way, we should have quadruplicate NHEJ values for most repair topology/cell population conditions, which will allow us to do statistical comparisons.  
#Remember that for each of the twelve wells you should calculate raw reporter expressions and a BFP/GFP normalized value. Then, for each intact/cut pair you can calculate an NHEJ value. In this way, we should have quadruplicate NHEJ values for most repair topology/cell population conditions, which will allow us to do statistical comparisons.  
Line 83: Line 121:
'''Reference information:'''
'''Reference information:'''


[[Image:S14M2_TR-inst-samples.png|thumb|left|300px|'''TR instructor samples.''']]
<center>
[[Image:S14M2_WF-inst-samples.png|thumb|center|250px|'''WF instructor samples.''']]
{| border="1"
!Day
!Tube #
!Condition
|-
|T/R
|1
|Mock transfection
|-
|T/R
|2
|GFP Intact Only
|-
|T/R
|3
|BFP Intact Only
|-
|W/F
|1
|Mock transfection
|-
|W/F
|2
|GFP Intact Only
|-
|W/F
|3
|BFP Intact Only
|}
</center>
 
<br style="clear:both;"/>
<br style="clear:both;"/>
[[Image:S14M2_worksheet-example.png|thumb|center|550px|'''Sample NHEJ calculator screenshot.''']]
[[Image:S14M2_worksheet-example.png|thumb|center|550px|'''Sample NHEJ calculator screenshot.''']]


<font color=FF33FF>'''You must email your Excel sheet to Shannon (T/R) or Leslie (W/F) before leaving lab today. We instructors will post a summary file for ease of class-wide data analysis by Wednesday evening or Thursday morning.'''</font color>
<font color=FF33FF>'''You must email your Excel sheet to Shannon (T/R) or Leslie (W/F) before leaving lab today. We instructors will post a summary file for ease of class-wide data analysis by Wednesday evening or Thursday morning.'''</font color>
==Reagent list==
*PBS
*Bio-Safe Coomassie Stain (Bio-Rad)
*Mostly your brains!


==Navigation Links==
==Navigation Links==

Latest revision as of 15:55, 7 April 2015


20.109(S15): Laboratory Fundamentals of Biological Engineering

Home        People        Schedule Spring 2015        Assignments        Lab Basics        OWW Basics       
DNA Engineering        System Engineering        Biomaterials Engineering              

Introduction

We hope that you’ll leave lab today with a sense of accomplishment, after inspecting your raw flow cytometry data and then calculating NHEJ repair values. Unfortunately or excitingly – depending on your perspective – it turns out in scientific research that the hard work is just beginning once the data is quantified! Interpreting the data and drawing (sometimes tentative) conclusions requires deep reading and thinking – a process that shouldn’t be rushed. To help get you started, let’s review a few key elements of DNA repair and of the NHEJ pathway in particular.

Our discussions of NHEJ have primarily been focused on Ku80 and DNA-PKcs, along with a few other key players such as Ligase IV, and will remain so here. However, the schematic below from the review by Grundy et al. highlights that many accessory molecules have their own roles to play. Recall that Ku80, with its dimer partner Ku70, completes the first step of NHEJ repair by binding to DNA double-strand breaks (DSBs). Keep this function in mind as you consider how a Ku80 knockout strain might respond to DNA damage. The Ku 80/70 dimer quickly recruits DNA-PKcs, the catalytic subunit of DNA-dependent protein kinase, to form the DNA-PK complex. Although DNA-PKcs has some binding affinity for DSBs, this affinity is increased by two orders of magnitude by the presence of the Ku dimer, and the kinase activity itself cannot proceed in the absence of Ku. Interestingly, although the kinase activity of DNA-PK is known to be important, it is not certain precisely which phosphorylation events are absolutely required for NHEJ.

NHEJ pathway overview from GJ Grundy et al., "One ring to bring them all—The role of Ku in mammalian non-homologous end joining" in DNA Repair 2014 TBD, in press

The one piece of wet lab work that you will do next time is complete your NHEJ inhibitor validation assay. Clonogenic assays of mammalian cells have over a 50 year history, as mentioned in the methods paper by Franken et al. They are useful for assessing the reproductive capacity of cells after irradiation and other types of damage. We will diverge somewhat from the Nature Protocols paper, but it is useful for introducing terms such as the plating efficiency and the surviving fraction. Specifically, we do not need to fix our cells in an independent step, because the stain that we will use contains methanol. (Correction! Our stain contains very little methanol, so fixing does not appear crucial for short-term staining.) Second, we will not use the crystal violet stain, which binds DNA, but instead a Coomassie derivative, which targets proteins. In fact, you may recognize Coomassie as the go-to stain for SDS-PAGE. Protein binding by the dye occurs primarily via arginine, as well as other basic and aromatic residues, as described here. We will use a variant of the original Coomassie Brilliant Blue stain called BioSafe Coomassie.

Most of your time today will be spent at the computer, quantifying flow cytometry data. Recall from the M2D4 introduction that we will proceed in three main steps.

First, reporter expression for GFP and BFP alike will be calculated by multiplying percentage of positive cells by fluorescence intensity (FI). We have a choice of whether to use mean, geometric mean, or median fluorescence intensity. Median fluorescence is least susceptible to being influenced by a few outliers, while geometric mean is generally more appropriate for log scale data than arithmetic mean. For normally distributed populations, all three values should be pretty similar. In practice, we have found that while mean and median FI are very different values, after normalization the ultimate NHEJ repair values are quite similar, so we will use the mean value.

The second step is to calculate the ratio of BFP to GFP reporter expression for each sample. The final step is divide the damaged-BFP:GFP ratio by the maximal possible “repair,” namely the intact-BFP:GFP ratio. Convince yourself that this parameter essentially provides the fraction of BFP plasmids repaired.

Protocols

Part 1: Paper discussion

As described in the Day 5 homework, we will be discussing the Goglia et al. paper in class today.

Technical Background

The paper by Goglia et al. utilizes a fluorescence based DNA repair sensor similar to the one that you are employing in Module 2. There are, however, some important differences in the construction and function of the EJ-RFP (end joining-red fluorescent protein) sensor versus the pMAX-BFP-MCS sensor that was constructed for 20.109. Another paper from the same lab, published in 2013, details the development of the EJ-RFP sensor. You do not need to read the entire paper, but make sure that you understand how the sensor works so that you can fully grasp the high throughput screen that was completed in the Goglia et al. manuscript.

In particular, please read the Introduction and the first two Results sections of the 2013 paper. You will find this background presentation to be helpful for understanding the DNA repair sensors in the Goglia et al. paper.

Discussion Topics

Content

The following questions will guide our in-class discussion; consider them as a starting point rather than a check-list.

(A) DNA repair background

  1. What is the difference between canonical NHEJ and (what the authors term) mutagenic NHEJ? What type of NHEJ does your sensor measure?
  2. How did the authors develop a specific screening tool for mNHEJ versus cNHEJ?


(B) Drug screening background

  1. What is the difference between a "reverse chemical genetic" screen and a "forward chemical genetic" screen? Why would you use one versus the other?
  2. What type of equipment did the authors use to perform the drug screen? Think about a couple reasons why this would be not only convenient, but also important for the study.
  3. Why was DMSO added at 1% in wells not containing drug?
  4. What was the purpose of adding Shield1 and TA? The authors state that the "absence" of these ligands is a positive control. What do they mean?
  5. What is an orthogonal assay? What is the purpose of performing these types of assays?
  6. What orthogonal assays were performed to confirm the original hits?
Figures & Results

We will not discuss all of the figures in this paper. Concentrate on the Results sub-sections and Figures outlined below. Be prepared to discuss all of the figures listed below. It is completely fine to have questions about the paper and to not fully grasp all of the material, but it is expected that you will have put forth a good faith effort to do so.

  1. Figure 1
    • Figures 1A and 1B are typical schematic diagrams that you find within journal papers. Why are these helpful and what specific information do you obtain from these sub-panels?
    • Figure 1C provides an example of the type of output data obtained. What factors do the authors report are important to achieve adequate cell segmentation?
    • The remainder of Figure 1 shows important control experiments. Answer the following questions while you read:
      • What controls are shown and why is it important to show these controls in a figure?
      • What is a Z'-factor and why do the authors use it?
      • Do you feel convinced that the data obtained in the large inhibitor screen will be believable after reading about and examining Figure 1?
  2. Figure 2
    • What is a RADaR plot and how do you read it? (Part of selling your science is coming up with memorable acronyms.)
    • Explain the significance of Figures 2B and 2C.
    • Why did the authors start with the LOPAC 1280 library (and what is it)?
  3. Figure 3
    • This figure shows a graphical representation of the 20,000 compound screen. How many times was this replicated? Where did the 20,000 compound library come from?
  4. Figure 4
    • This is another great example of an useful schematic diagram in this paper. Consider all of the information that is contained in this small flowchart and, as you read, keep track of how many times you reference it.
    • As you put together your Mod2 report, think about how you might use schematic diagrams to help the reader understand your study.
  5. Figure 5
    • What is RU-0084411 and why is it an interesting hit in the screen? Why might the authors (and pharmaceutical companies) be especially interested in following up on this type of hit?
    • The curves shown under Figure 5A-2&3 are generally referred to as 'dose-response' or 'inhibition' curves. Many dose-response curves have a sigmoidal shape. How does one estimate the IC50 from analyzing this type of data?
    • Do any of the plots shown in Figure 5A give you pause with respect to future use of Mibrefradil as a clinical NHEJ inhibitor?
  6. Figure 6
    • What is an orthogonal assay in the context of this paper? Why is it important to do them?
Discussion & Conclusions

Please read the entirety of the Discussion section.

  • List three reasons why the authors state that their study is novel. What type of evidence do they use to convince you?
  • List a couple limitations of the paper (that the authors address in this section).

The purpose of a Discussion section is (at least) four-fold:

  1. Provide a summary and explanation of the data in the paper. This is the place to do all of your interpretation. For example, in the third paragraph of the Discussion section that starts "We identified several novel molecules...", the authors admit to being surprised at some of their findings. They then postulate why these findings might be real and suggest further studies that would be required to further tease apart the current data.
  2. Convince the audience that your study makes a contribution to the field. The Discussion section is the place to compare and contrast your current results with those that have already been published. Why are your results interesting and important? Re-visit your Introduction -- what was your 'big picture' motivation? How did your study impact that?
  3. Admit your limitations. No study is perfect, don't let anyone tell you that it is! Perhaps your data doesn't quite get to the answer and there is a technical limitation -- tell the audience. Perhaps the cell system you are using isn't the optimal one (which may or may not be available) -- tell the audience. Perhaps the data from your DNA repair assay is noisy and you know why -- tell the audience. The Discussion section should admit to limitations and suggest specific ways to address them.
  4. Suggest the next big thing. Where does your study leave off? Since you are now the expert -- what is the next most important thing to do?!?

Part 2: Flow cytometry analysis

Overview:

  • You will begin by looking at images from the instructor samples to learn how to read the flow cytometry plots and summary statistics.
  • Next you will peek at your own images and form preliminary expectations about your data set.
  • Finally, you will work in Excel to precisely calculate the NHEJ repair value for each of your three conditions (two replicates each).

Protocol:

  1. The pdf files with your data are posted on the M2D6 Talk page.
  2. The instructor samples are listed in the table below. From this table, and from the T/R and W/F image sets, try to address the questions below.
    • Background. The scatter data is used – in three steps – to make gate P3, which should consist primarily single cells. Next a gate that we called Live cells was set based upon the addition ToPro3 to the media. ToPro3 can only pass through the membranes of dead cells, staining them with a dye that fluoresces when exited with 647 nm wavelength light. The cytometer we used calls this channel the APC channel (because the dye APC also fluoresces at that wavelength). So, using the plot that shows FSC vs APC we can gate-in the live cells (exclude the dead ToPro3+ cells).
  3. From the cells gated in Live Cells, two sub-gates are made that capture all GFP-positive cells ("Green cells" gate) and all BFP-positive cells ("Blue cells" gate). Both singly and doubly positive cells are included in each gate. It is important to read the "% Parent" statistics: these indicate XFP-positive cells as a percentage of all the cells in Live Cells. The "% Total" statistics include debris, aggregates, and clearly dead cells!
    • What percent Green cells are in the mock sample on each day? What about Blue cells?
    • What percent of singly-transfected cells express GFP? Do cross-day replicates agree well or not?
    • What percent of singly-transfected cells express BFP? Do cross-day replicates agree well or not?
  4. Now, start to look at your K1-intact conditions (and possibly those of your classmates).
    • What percent of co-transfected cells express GFP? Express BFP? How many express both?
    • How is within-day and cross-day replicate agreement for the co-transfected samples?
  5. Answer the following by looking at a team that used DMNB (hint: there is a spreadsheet on the Talk page that will help you locate those samples).
    • Does DMSO appear to affect scatter profiles? What about affecting co-expression?
    • Hint: you'll need to compare the K1 intact samples from a DMNB group versus a different group.
  6. After you understand the instructor data, skim over your 12 sample plots. Can you see apparent differences between K1, K1+inhibitor, and xrs6?
  7. Now that you have a good conceptual understanding of the data, it's time to crunch some numbers. Open the .csv file and save it as a newly named .xlsx file.
  8. Begin by deleting all of the rows except the twelve containing your own dataset.
  9. Next delete all of the columns except the few that interest you. Keep in mind that you need to know Green cell and Blue cell gating as a % of the parent gate, Live Cells. Class-wide, you are only required to do your calculations based on mean fluorescence intensity (MFI), but you should also keep the median data in case others want to use it.
  10. We recommend that you prepare a new Excel file with your NHEJ equations, and just copy-paste in the appropriate % and MFI data; this approach is a versatile one. Your final worksheet might look similar to the screenshot below.
  11. Remember that for each of the twelve wells you should calculate raw reporter expressions and a BFP/GFP normalized value. Then, for each intact/cut pair you can calculate an NHEJ value. In this way, we should have quadruplicate NHEJ values for most repair topology/cell population conditions, which will allow us to do statistical comparisons.

Reference information:

Day Tube # Condition
T/R 1 Mock transfection
T/R 2 GFP Intact Only
T/R 3 BFP Intact Only
W/F 1 Mock transfection
W/F 2 GFP Intact Only
W/F 3 BFP Intact Only


Sample NHEJ calculator screenshot.

You must email your Excel sheet to Shannon (T/R) or Leslie (W/F) before leaving lab today. We instructors will post a summary file for ease of class-wide data analysis by Wednesday evening or Thursday morning.

Navigation Links

Previous Day: DNA repair assays

Next Day: Data analysis